PT - JOURNAL ARTICLE AU - Martin Maripuu AU - Marie Bendix AU - Louise Öhlund AU - Micael Widerström AU - Ursula Werneke TI - Death associated with coronavirus (COVID-19) infection in individuals with severe mental disorders in Sweden during the early months of the outbreak – a exploratory cross-sectional analysis of a population-based register study AID - 10.1101/2020.09.14.20193987 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.14.20193987 4099 - http://medrxiv.org/content/early/2020/09/18/2020.09.14.20193987.short 4100 - http://medrxiv.org/content/early/2020/09/18/2020.09.14.20193987.full AB - Background Individuals with severe mental disorder (SMD) have a higher risk of somatic comorbidity and mortality than the rest of the population. We set up a population-based study to assess whether individuals with SMD had a higher risk of death associated with a COVID-19 infection (COVID-19 associated death) than individuals without SMD.Methods Exploratory analysis with a cross-sectional design in the framework of a population-based register study covering the entire Swedish population. The Swedish Board for Health and Welfare (Socialstyrelsen) provided anonymised tabulated summary data for further analysis. We compared numbers of COVID-19 associated death in individuals with SMD (cases) and without SMD (controls). We calculated the odds ratio (OR) for the whole sample and by age group and four potential risk factors, namely diabetes, cardiovascular disease, hypertension, chronic lung disease.Results The sample comprised of 7,923,859 individuals, 103,999 with SMD and 7,819,860 controls. There were 130 (0.1%) COVID-19 associated deaths in the SMD group and 4945 (0.06%) in the control group, corresponding to an OR of 1.98 (CI 1.66-2.35; p < 0.001). The odds were fourfold in the age group between 60 and 79 years. Cardiovascular diseases increased the odds by 50%. Individuals with SMD without any of the risk factors under study had three-folds odds of COVID-19 associated death.Conclusion Our preliminary results suggest that individuals with SMD are a further group at increased risk of COVID-19 associated death. The factors contributing to this increased mortality risk require clarification.Competing Interest StatementUrsula Werneke has received funding for educational activities on behalf of Norrbotten Region (Masterclass Psychiatry Programme 2014-2018 and EAPM 2016, Lulea, Sweden): Astra Zeneca, Eli Lilly, Janssen, Novartis, Otsuka/Lundbeck, Servier, Shire and Sunovion. Martin Maripuu, Marie Bendix, Micael Widerstrom and Louise Ohlund declare that there is no conflict of interest.Funding StatementThis work was supported by the County Council of Jamtland/Harjedalen and the Department of Clinical Sciences, Umea University and the Department of Psychiatry, Sunderby Hospital, Lulea, Region Norrbotten, Sweden.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority (DNR 2020-02759) and conducted according to the declaration of Helsinki. The data originated from routine information collected by the Swedish Board of Health and Welfare, which was then made available as summary data in anonymised form. As this data was only provided in anonymised form, informed consent was not required. Potentially identifiable data was withheld by the Swedish Board of Health and Welfare (data withheld due to confidentiality reasons).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe summary tables provided by the Swedish Board of Health and Welfare are already included in this article. Requests for the original summary tables provided will be taken up with Swedish Board of Health and Welfare.